Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FG61X
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,893
Award facts
- Contract value 100% obligated
- $1,892.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, issued on July 29, 2025, awards DMS Pharmaceutical Group Inc. a firm fixed-price contract to supply NUCALA 100 mg/ml auto-injector units to the Defense Logistics Agency. Valued at $1,892.90 with an ultimate completion date of July 30, 2025, this order carries no set-aside designation. The product will be delivered to a facility in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, holds a substantial single-award Indefinite Delivery Contract with DLA under the SPE2DB program valued at $499.999 billion through November 2026, which serves as the underlying vehicle for this delivery order.
NUCALA (mepolizumab) is a biologic medication used primarily in the treatment of eosinophilic conditions and severe asthma. As a pharmaceutical wholesaler specializing in supplying branded medications, biologics, and medical consumables to federal healthcare systems and military facilities, DMS Pharmaceutical Group maintains a robust portfolio of delivery orders through its IDC with DLA. This delivery order reflects the company's continued role as a critical supplier within the federal pharmaceutical supply chain, facilitating the distribution of specialized pharmaceutical products to Department of Defense healthcare sites.
Quick answers
Who was awarded contract SPE2DB25FG61X?
SPE2DB25FG61X was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 29, 2025.
How much is contract SPE2DB25FG61X worth?
The government has obligated $1,893 on SPE2DB25FG61X.
Is contract SPE2DB25FG61X an order under another contract?
Yes. SPE2DB25FG61X is a delivery order under SPE2DB20D9157, an indefinite delivery contract.
Was contract SPE2DB25FG61X competed?
The extent of competition for SPE2DB25FG61X was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award